发明授权
US08859234B2 Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function
有权
融合构建体及其使用以产生具有增加的Fc受体结合亲和力和效应子功能的抗体
- 专利标题： Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function
- 专利标题（中）： 融合构建体及其使用以产生具有增加的Fc受体结合亲和力和效应子功能的抗体
-
申请号： US13759925申请日： 2013-02-05
-
公开(公告)号： US08859234B2公开(公告)日： 2014-10-14
- 发明人: Pablo Umaña , Peter Bruenker , Claudia Ferrara , Tobias Suter
- 申请人： Roche GlycArt AG
- 申请人地址： CH Schlieren-Zürich
- 专利权人： Roche GlycArt AG
- 当前专利权人： Roche GlycArt AG
- 当前专利权人地址： CH Schlieren-Zürich
- 代理机构： Sterne, Kessler, Goldstein & Fox, PLLC
- 主分类号： C12P21/04
- IPC分类号： C12P21/04 ; C12P21/08 ; C07K16/28 ; C12N9/24 ; C07K16/30 ; C12N15/62 ; C12N9/10 ; C07K16/32 ; C12P21/00 ; A61K38/00 ; A61K39/00
摘要：
The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to nucleic acid molecules, including fusion constructs, having catalytic activity and the use of same in glycosylation engineering of host cells to generate polypeptides with improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
公开/授权文献
信息查询
